الفهرس 
Hepatocellular carcinoma (HCC)Only 14 pages are availabe for public view
 |  | from | 175 |  |  |
| | | from | 175 | | |
Abstract
Summary and conclusion
Hepatocellular carcinoma (HCC) is one of the most common malignant
tumors worldwide. In Egypt, the incidence of HCC has doubled in the past 10
years and it is now the second most incident and lethal cancer.
Early detection is critically important because the effective treatment for
HCC is surgical resection or ablation therapy when the tumor is small.
Up to 20% of HCC cases do not produce AFP, even when very large, and
slight increases are usual in acute hepatitis, chronic hepatitis and cirrhosis and
overlaps can cause diagnostic difficulties.
Thus, the identification of novel biochemical markers for HCC remains
an important goal for many laboratories around the world. One of these
biomarkers is “Fucosylated Haptoglobin”.
Our study was performed to evaluate fucosylated haptoglobin as a
biomarker for hepatocellular carcinoma in Egyptian patients.
This prospective study was carried out on 60 patients classified into three
groups; group (I): 20 patients with HCC, group (II): 20 patients with
cirrhotic liver disease without HCC and group (III) (the control group): 20
apparently healthy individuals.
Inclusion criteria were adult patient, diagnosis of liver cirrhosis (based
on clinical, biochemical and radiological criteria “by US (coarse echogenic
pattern, bulky caudate lobe, attenuated hepatic veins” with or without liver
biopsy)) and diagnosis of HCC was by the following criteria: Pathological
HCC diagnosis by percutaneous biopsy, or Clinical and radiological (by
ultrasound and triphasic CT). Exclusion criteria were: patient refusal, diabetes
mellitus, chronic renal impairment, patients with extrahepatic metastases,
other neoplasm, previous history of HCC ablation and pathological or
radiological evidence of mixed HCC-cholangio cellular carcinoma.